ClinicalTrials.gov
public full text
Public Domain
First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4
The purpose of this first-in-man Phase I study is to determine whether the CXCR4-inhibitor ALX-0651 is safe and effective after single or multiple intravenous administrations to healthy male volunteers.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants#230362
- Phase I Study of HXN6005 in Adult Healthy Participants#845998
- Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease#848819
- A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis#910991
- A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy#889930
Record · ID 902317
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive